Drug Profile
MP 4
Alternative Names: Apogen - multiple sclerosis; Apogen MSLatest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer Alexion Pharmaceuticals; National Institutes of Health (USA)
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 02 Feb 2017 Discontinued - Phase-I for Multiple sclerosis in USA (IV)
- 31 Jan 2003 Suspended - Phase-I for Multiple sclerosis in USA (unspecified route)